Meiji Seika Pharma initiates ME3241 Phase I study, inverting checkpoint blockade logic for autoimmune therapy
Meiji Seika Pharma initiates Phase I of ME3241, a PD-1 agonist antibody for autoimmune disease in Australia. Read the clinical analysis.
Meiji Seika Pharma’s alliance with MBC BioLabs signals a bold shift in global R&D sourcing strategy
Meiji Seika Pharma Co., Ltd. has announced a strategic partnership with MBC BioLabs, a leading biotech incubator based in California’s San Francisco Bay Area, to expand its global drug discovery initiatives. The Tokyo-headquartered pharmaceutical firm aims to deepen its open innovation approach by tapping into early-stage biotech talent in the United States, with a focus […]